Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

Figures & data

Table 1 Patients characteristics (n=15)

No	Subtype	Gender	Age	Stage	B symptoms	ECOG Performance	Elevated LDH	Extra-nodal Site >1	IPI Score	Efficacy
1	AITL	M	61	I	No	1	No	No	1	CR
2	ALCL (ALK negative)	M	55	II	No	0	No	No	0	CR
3	PTCL-NOS	F	54	III	Yes	0	No	No	1	CR
4	AITL	M	69	III	Yes	0	No	No	2	CR
5	PTCL-NOS	M	39	III	Yes	0	No	No	1	PR
6	PTCL-NOS	M	65	III	Yes	0	No	No	2	PD
7	PTCL-NOS	M	53	III	Yes	1	No	No	1	PR
8	PTCL-NOS	M	57	II	Yes	0	No	No	0	CR
9	AITL	F	63	II	No	0	No	No	1	CR
10	PTCL-NOS	M	58	II	No	0	No	No	0	SD
11	PTCL-NOS	M	47	I	No	0	No	No	0	PD
12	PTCL-NOS	M	46	IV	No	0	Yes	Yes	3	PR
13	PTCL-NOS	M	43	III	No	1	No	No	1	PR
14	PTCL-NOS	M	48	II	No	0	No	No	0	CR
15	PTCL-NOS	F	61	III	No	0	No	No	2	CR

Abbreviations: AITL, angioimmunoblastic T cell lymphoma; ALCL, anaplastic large cell lymphoma; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PTCL, peripheral T cell lymphoma; NOS, not otherwise specified; CR, complete response; PR, partial response; SD, stable disease.

Figure 1 Outcomes of patients treated with ECHOP (Recombinant human endostatin in combination with CHOP regimen).

Notes: (A) Progression-free survival (PFS); (B) overall survival (OS); (C) PFS based on histology; (D) OS based on histology; (E) PFS based on VEGFR2 expression; (F) OS based on VEGFR2 expression.
Abbreviations: PTCL, peripheral T cell lymphomas; NOS, not otherwise specified; AITL, angioimmunoblastic T cell lymphoma; VEGFR2, vascular endothelial growth factor receptor 2.

Figure 2 The expression of VEGFR2 in tumor vessels.

Notes: (A) Overexpression of VEGFR2 in tumor vessel with brown stain (magnification ×200) and (B) lower expression of VEGFR2 in tumor vessels with dark yellow stain (magnification ×200).
Abbreviation: VEGFR2, vascular endothelial growth factor receptor 2.

Table 2 VEGFR2 expression and outcomes

Patient number	Score (IRS)	Subtypes	Efficacy	Progress	Survival
9	10	AITL	CR	No	Yes
4	8	AITL	CR	No	Yes
14	8	PTCL-NOS	CR	No	Yes
5	8	PTCL-NOS	PR	No	Yes
3	6	PTCL-NOS	CR	Yes	Yes
8	6	PTCL-NOS	CR	No	Yes
12	6	PTCL-NOS	PR	Yes	No
15	4	PTCL-NOS	CR	Yes	No
7	4	PTCL-NOS	PR	No	Yes
6	4	PTCL-NOS	PD	Yes	No
11	4	PTCL-NOS	PD	Yes	No

Abbreviations: PTCL, peripheral T cell lymphoma; NOS, not otherwise specified; CR, complete response; AITL, angioimmunoblastic T cell lymphoma; IRS, immunoreactive score; PR, partial response.

Table 3 Toxicity (n=15)

	Grade I/II		Grade III/IV
	N	%	N	%
Hematologic parameters
Neutropenia	2	13.3	13	86.7
Febrile neutropenia	0	0	4	26.7
Anemia	10	66.7	0	0
Thrombocytopenia	1	6.7	0	0
Nonhematologic parameters
Fatigue	5	33.3	0	0
Vomiting	5	33.3	0	0
Diarrhea	4	26.7	0	0
Headache	4	26.7	0	0
Chest tightness	2	13.3	0	0
Fever	2	13.3	0	0
Constipation	2	13.3	0	0
Infection	1	6.7	0	0
Neurotoxicity	1	6.7	0	0
Aminotransferase abnormality	1	6.7	0	0